YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer

A. Roslind; A.S. Knoop; Maiken Brit Jensen; J.S. Johansen; D.L. Nielsen; P.A. Price; E. Balslev

YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer

A. Roslind, A.S. Knoop, Maiken Brit Jensen, J.S. Johansen, D.L. Nielsen, P.A. Price, E. Balslev

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

31 Citationer (Scopus)

Abstract

YKL-40 is a new biomarker in serum with a prognostic value in several localized and metastatic malignancies. The current knowledge regarding the biological functions of YKL-40 in cancer links YKL-40 to increased aggressiveness of the tumor. Utilizing tissue microarrays, YKL-40 protein expression in tumor tissue was assessed by immunohistochemistry in a cohort of 630 high-risk breast cancer patients with a median estimated potential follow-up time of 10 and 13 years for disease-free (DFS) and overall survival (OS), respectively. YKL-40 protein expression was found in malignant tumor cells and in inflammatory cells. High expression was associated with positive estrogen and progesterone receptor status and high tumor differentiation. Contrary to studies on serum YKL-40 as a prognostic biomarker, a high YKL-40 expression in tumor cells was not significantly associated with DSF and OS in univariate and multivariate analyses
Udgivelsesdato: 2008/11

Originalsprog	Engelsk
Tidsskrift	Breast Cancer Research and Treatment
Vol/bind	112
Udgave nummer	2
Sider (fra-til)	275-285
Antal sider	10
ISSN	0167-6806
Status	Udgivet - 2008

Bibliografisk note

Times Cited: 0Proceedings PaperEnglishRoslind, AHerlev Univ Hosp, Dept Oncol, Herlev Ringvej 75, DK-2730 Copenhagen, DenmarkCited References Count: 45360NOSPRINGER233 SPRING ST, NEW YORK, NY 10013 USANEW YORK

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

@article{aa200e10066311deb05e000ea68e967b,

title = "YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer",

abstract = "YKL-40 is a new biomarker in serum with a prognostic value in several localized and metastatic malignancies. The current knowledge regarding the biological functions of YKL-40 in cancer links YKL-40 to increased aggressiveness of the tumor. Utilizing tissue microarrays, YKL-40 protein expression in tumor tissue was assessed by immunohistochemistry in a cohort of 630 high-risk breast cancer patients with a median estimated potential follow-up time of 10 and 13 years for disease-free (DFS) and overall survival (OS), respectively. YKL-40 protein expression was found in malignant tumor cells and in inflammatory cells. High expression was associated with positive estrogen and progesterone receptor status and high tumor differentiation. Contrary to studies on serum YKL-40 as a prognostic biomarker, a high YKL-40 expression in tumor cells was not significantly associated with DSF and OS in univariate and multivariate analyses Udgivelsesdato: 2008/11",

author = "A. Roslind and A.S. Knoop and Jensen, {Maiken Brit} and J.S. Johansen and D.L. Nielsen and P.A. Price and E. Balslev",

note = "Times Cited: 0Proceedings PaperEnglishRoslind, AHerlev Univ Hosp, Dept Oncol, Herlev Ringvej 75, DK-2730 Copenhagen, DenmarkCited References Count: 45360NOSPRINGER233 SPRING ST, NEW YORK, NY 10013 USANEW YORK",

year = "2008",

language = "English",

volume = "112",

pages = "275--285",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer

AU - Roslind, A.

AU - Knoop, A.S.

AU - Jensen, Maiken Brit

AU - Johansen, J.S.

AU - Nielsen, D.L.

AU - Price, P.A.

AU - Balslev, E.

N1 - Times Cited: 0Proceedings PaperEnglishRoslind, AHerlev Univ Hosp, Dept Oncol, Herlev Ringvej 75, DK-2730 Copenhagen, DenmarkCited References Count: 45360NOSPRINGER233 SPRING ST, NEW YORK, NY 10013 USANEW YORK

PY - 2008

Y1 - 2008

N2 - YKL-40 is a new biomarker in serum with a prognostic value in several localized and metastatic malignancies. The current knowledge regarding the biological functions of YKL-40 in cancer links YKL-40 to increased aggressiveness of the tumor. Utilizing tissue microarrays, YKL-40 protein expression in tumor tissue was assessed by immunohistochemistry in a cohort of 630 high-risk breast cancer patients with a median estimated potential follow-up time of 10 and 13 years for disease-free (DFS) and overall survival (OS), respectively. YKL-40 protein expression was found in malignant tumor cells and in inflammatory cells. High expression was associated with positive estrogen and progesterone receptor status and high tumor differentiation. Contrary to studies on serum YKL-40 as a prognostic biomarker, a high YKL-40 expression in tumor cells was not significantly associated with DSF and OS in univariate and multivariate analyses Udgivelsesdato: 2008/11

AB - YKL-40 is a new biomarker in serum with a prognostic value in several localized and metastatic malignancies. The current knowledge regarding the biological functions of YKL-40 in cancer links YKL-40 to increased aggressiveness of the tumor. Utilizing tissue microarrays, YKL-40 protein expression in tumor tissue was assessed by immunohistochemistry in a cohort of 630 high-risk breast cancer patients with a median estimated potential follow-up time of 10 and 13 years for disease-free (DFS) and overall survival (OS), respectively. YKL-40 protein expression was found in malignant tumor cells and in inflammatory cells. High expression was associated with positive estrogen and progesterone receptor status and high tumor differentiation. Contrary to studies on serum YKL-40 as a prognostic biomarker, a high YKL-40 expression in tumor cells was not significantly associated with DSF and OS in univariate and multivariate analyses Udgivelsesdato: 2008/11

M3 - Journal article

SN - 0167-6806

VL - 112

SP - 275

EP - 285

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -